SCHEMBL29660299

SCHEMBL29660299

CCOc1ccc(-c2nc(C(=O)OC(C)(C)C)c(C(O)C(C)C)s2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.40
TSHR P16473 2/20 0.40
ALPL P05186 1/20 0.39
ALPI P09923 1/20 0.39
TARBP2 Q15633 1/20 0.39
MAPT P10636 7/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HIF1A Q16665 1/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PTPN11 Q06124 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660360 0.92 TARBP2 (0.41) HSD17B10TSHRALPLALPITARBP2
SCHEMBL29660332 0.85 MMP13 (0.39) HSD17B10TSHRALPLALPITARBP2
SCHEMBL29660334 0.82 TARBP2 (0.44) HSD17B10ALPLALPITARBP2MAPT
SCHEMBL29660324 0.81 MAPT (0.42) HSD17B10TSHRALPLALPIMAPT
SCHEMBL29660317 0.81 PTPN11 (0.44) HSD17B10TSHRALPLALPIMAPT
SCHEMBL29660409 0.80 MAPT (0.46) HSD17B10ALPLALPITARBP2MAPT
SCHEMBL29660340 0.79 MAPT (0.40) HSD17B10TSHRALPLALPIMAPT
SCHEMBL29660346 0.77 MAPT (0.42) HSD17B10TSHRALPLALPIMAPT
SCHEMBL29660337 0.76 KDM4E (0.42) HSD17B10TSHRTARBP2MAPTALDH1A1
SCHEMBL29911091 0.76 MAPT (0.41) HSD17B10TSHRALPLALPIMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP HSD17B10 227/4885TSHR 2112/4885ALPL 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.